Accendra Health Forecasts 10-Cent Loss, 75% Revenue Plunge for Q1
ACH has more than doubled off its 52-week low of $1.84.
Summary
Analysts expect Accendra Health Inc. to report a loss of 10 cents per share and a substantial 75.5% decrease in quarterly revenue to $644.636 million for the period ending March 31, 2026. This significant anticipated decline follows the company's 2025 10-K, which disclosed a net loss of $1.1 billion and negative shareholder equity, indicating persistent and severe financial headwinds. The projected massive revenue drop and continued unprofitability are highly material for the company, suggesting a significant deterioration in its operational performance. Traders will be closely watching the actual Q1 results on May 11 to confirm if the company meets, beats, or misses these significantly lowered expectations, which could trigger further stock price volatility.
At the time of this announcement, ACH was trading at $3.74 on NYSE in the Life Sciences sector, with a market capitalization of approximately $285.9M. The 52-week trading range was $1.84 to $9.55. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.